YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Hydrocodone | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Magnesium sulfate | The therapeutic efficacy of YKP-1358 can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | YKP-1358 may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Orphenadrine | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Rotigotine | YKP-1358 may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with YKP-1358. |
| Sodium oxybate | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Thalidomide | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with YKP-1358. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with YKP-1358. |
| Dicoumarol | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when YKP-1358 is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when YKP-1358 is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when YKP-1358 is combined with (S)-Warfarin. |
| Mirtazapine | YKP-1358 may increase the serotonergic activities of Mirtazapine. |
| Ethanol | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | YKP-1358 may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with YKP-1358. |
| Seproxetine | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when YKP-1358 is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Alaproclate. |
| Methylene blue | YKP-1358 may increase the serotonergic activities of Methylene blue. |
| Zopiclone | The risk or severity of adverse effects can be increased when YKP-1358 is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with YKP-1358. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with YKP-1358. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with YKP-1358. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of YKP-1358. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with YKP-1358. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with YKP-1358. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with YKP-1358. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with YKP-1358. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with YKP-1358. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with YKP-1358. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with YKP-1358. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with YKP-1358. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with YKP-1358. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with YKP-1358. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with YKP-1358. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with YKP-1358. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with YKP-1358. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with YKP-1358. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with YKP-1358. |
| Venlafaxine | The risk or severity of serotonin syndrome can be increased when YKP-1358 is combined with Venlafaxine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with YKP-1358. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with YKP-1358. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with YKP-1358. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with YKP-1358. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with YKP-1358. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with YKP-1358. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with YKP-1358. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with YKP-1358. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with YKP-1358. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with YKP-1358. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with YKP-1358. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with YKP-1358. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with YKP-1358. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with YKP-1358. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with YKP-1358. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with YKP-1358. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with YKP-1358. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with YKP-1358. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with YKP-1358. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with YKP-1358. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with YKP-1358. |